<DOC>
	<DOCNO>NCT01420770</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy daily oral dos 300 mg , 400 mg , 500 mg SAR302503 reduction spleen volume determine magnetic resonance imaging ( MRI ) . Secondary Objectives : - To evaluate safety SAR302503 . - To evaluate pharmacokinetics ( PK ) SAR302503 single repeat dos . - To evaluate pharmacodynamics SAR302503 measure change JAK2V617F allele burden patient JAK2V617F mutation , change substrate phosphorylation JAK-STAT signal transduction pathway , expression cytokine . - To measure improvement baseline Myeloproliferative Neoplasm ( MPN ) associate symptom , well overall impact quality life ( QOL ) , serial administration Myeloproliferative Neoplasm Symptom Assessment Form ( MPN-SAF ) . - To measure generic health-related quality life ( HRQL ) utility value use EQ-5D questionnaire .</brief_summary>
	<brief_title>Phase 2 Study SAR302503 Patients With Myelofibrosis</brief_title>
	<detailed_description>The duration study individual patient include period assess eligibility ( screen period 28 day ) , follow treatment period least 1 cycle ( 28 day ) study treatment , end-of-treatment visit least 30 day follow last administration study drug . However , treatment may continue patient derive benefit unacceptable toxicity meet study withdrawal criterion . The study duration approximately 16 month include 3-month enrollment period follow 12-month treatment period follow last patient enrol follow 30-day follow-up period . The cut-off date analysis primary endpoint response maximum end 3 month date first dose study drug last treated patient . The final analysis perform last enrolled patient complete Cycle12 assessment .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Diagnosis primary postpolycythemia vera postessential thrombocythemia myelofibrosis ( PostET MF ) accord 2008 World Health Organization ( WHO ) criteria Myelofibrosis classify highrisk intermediaterisk level 2 , define International Working Group Myelofibrosis Research Treatment ( IWGMRT ) Enlarged spleen , palpable least 5 cm costal margin At least 18 year age . Eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 study entry . Adequate organ function Absence active malignancy MF , except adequately treat basal cell carcinoma squamous cell carcinoma skin , cervical carcinoma situ malignancy stable therapy 5 year . Written inform consent participate . Willing comply schedule visit , treatment plan , laboratory assessment , studyrelated procedure . Exclusion criterion : Splenectomy . Any chemotherapy ( eg , hydroxyurea ) , immunomodulatory drug therapy ( eg , thalidomide , interferonalpha ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( eg , erythropoietin ) , hormone ( eg , androgen , danazol ) within 14 day prior initiation study drug ; darbepoetin use within 28 day prior initiation study drug . Major surgery therapy within 28 day radiation within 6 month prior initiation study drug . Concomitant treatment use pharmaceutical herbal agent know least moderate inhibitor inducer Cytochrome P450 3A4 ( CYP3A4 ) , unless approve sponsor . Active acute infection require antibiotic . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . Participation study investigational agent ( drug , biologic , device ) within 30 day , unless nontreatment phase . Prior treatment Janus kinase 2 ( JAK 2 ) Inhibitor , Contraindications undergo Magnetic resonance imaging ( MRI ) ( eg . metal implant ) . Pregnant lactate female . Women childbearing potential , unless use effective contraception study drug . Men partner woman childbearing potential , unless agree use effective contraception study drug . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . Clinically active hepatitis B C. Any severe acute chronic medical , neurological , psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , Investigator 's opinion , would make patient inappropriate entry study . Unable swallow capsule Presence gastric disorder would inhibit absorption oral medication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>